1. Search Result
Search Result
Results for "

BTB

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

2

Peptides

1

Inhibitory Antibodies

24

Recombinant Proteins

9

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-149164
    BTB09089
    1 Publications Verification

    GPR65 Neurological Disease Inflammation/Immunology
    BTB09089 is a T cell death-associated gene 8 (TDAG8/GPR65) specific agonist. BTB09089 increases TDAG8 expression and regulates the cytokine production of T cells and macrophages .
    BTB09089
  • HY-108705
    BI-3802
    3 Publications Verification

    Molecular Glues Bcl-2 Family Cancer
    BI-3802, a chemical probe, is a highly potent BCL6 degrader and inhibits the Bric-à-brac (BTB) domain of BCL6 with an IC50 of ≤3 nM. BI-3802 induces the polymerization of BCL6 and promotes BCL6 degration depended on E3 ligase SIAH1. BI-3802 has antitumor activity .
    BI-3802
  • HY-172736

    PROTACs BCL6 CD20 Cancer
    BMS-986458 is a highly selective, orally active cereblon-based BCL6 PROTAC degrader and antitumor agent. BMS-986458 selectively degrades BCL6 by binding cereblon to the BTB domain of BCL6, thereby regulating the cell cycle, antiproliferative and interferon signaling pathways, and upregulating the expression and distribution of CD20. BMS-986458 modulates the phenotype of follicular helper T cells and reduces circulating tumor DNA levels. The combination of BMS-986458 with CD20xCD3 bispecific antibody also enhances the efficiency of T cell tumor infiltration and expansion. BMS-986458 induces regression of BCL6-positive tumors and prolongs survival, and it is suitable for research related to B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and relapsed/refractory lymphoma .
    BMS-986458
  • HY-15877
    BTB06584
    2 Publications Verification

    ATP Synthase Cancer
    BTB06584 is a selective and IF1-dependent mitochondrial F1Fo-ATPase inhibitor without compromising ATP synthesis. BTB06584 can delays ischaemic cell death .
    BTB06584
  • HY-101770
    BTB-1
    1 Publications Verification

    Kinesin Microtubule/Tubulin Cancer
    BTB-1 is a potent, selective and reversible mitotic motor protein Kif18A inhibitor with an IC50 of 1.69 μM.
    BTB-1
  • HY-111381
    BI-3812
    3 Publications Verification

    BCL6 Cancer
    BI-3812, a chemical probe, is a highly efficient BCL6 inhibitor that is capable of suppressing the BTB domain of BCL6, with an IC50 value of ≤ 3 nM, exhibiting antitumor activity .
    BI-3812
  • HY-161138

    BCL6 Apoptosis Cancer
    WK369 is a novel BCL6 small molecule inhibitor, which exhibits excellent anti-ovarian cancer bioactivity, induces cell cycle arrest and causes apoptosis. WK369 can directly bind to the BCL6-BTB domain and block the interaction between BCL6 and SMRT, leading to the reactivation of p53, ATR and CDKN1A .
    WK369
  • HY-P1848
    Pep-1 (uncapped)
    2 Publications Verification

    Interleukin Related Cancer
    Pep-1 (uncapped) is a specific ligand of IL-13Ra2. Pep-1 (uncapped) exerts cell penetrating activity through receptor-mediated endocytosis, can cross the blood-tumor barrier (BTB) and target glioma cells. Pep-1 (uncapped) can enhance the uptake of nanoparticles by tumor cells and enhance the cell penetration ability of nanoparticles, and can be used to develop targeted drug delivery systems for glioma .
    Pep-1 (uncapped)
  • HY-162152

    Keap1-Nrf2 Inflammation/Immunology
    biKEAP1 (compound 3) is an inhibitor targeting the dimerKEAP1. biKEAP1 binds to cellular KEAP1 dimers and releases the NRF2 protein sequestered by KEAP1, resulting in immediate activation of NRF2. biKEAP1 also promotes nuclear translocation of NRF2 and directly inhibits proinflammatory cytokine transcription. biKEAP1 can reduce acute inflammation and reduce inflammatory damage in acute inflammation models .
    biKEAP1
  • HY-P991571

    GC-1118A

    EGFR PERK Akt Cancer
    GC1118 (GC-1118A) is a fully human anti-EGFR monoclonal antibody with binding affinity of 0.16 nM (KD) to EGFR. GC1118 displays potent inhibitory effects on high- and low-affinity EGFR ligand-induced signaling. GC1118 shows potent anti proliferative activity in KRAS wild-type and KRAS mutant cells. GC1118 can reach the tumor by crossing both BBB (blood-brain barrier) and BTB (brain-tumor barrier) and shows superior anti-tumor effects in various mice xenograft models. GC1118 can be used for the researches of cancer, such as colorectal cancer .
    GC1118
  • HY-177755

    Molecular Glues BCL6 Cancer
    BCL6-IN-10 (Compound 6) is a selective partially degradable molecular glue inhibitor that targets the BTB domain of BCL6 with an IC50 of 4 nM. BCL6-IN-10 shows anti-proliferative effect in diffuse large B-cell lymphoma (DLBCL) cell lines. BCL6-IN-10 can be used for the research of cancer .
    BCL6-IN-10
  • HY-W133897

    Biochemical Assay Reagents Others
    tert-Butylamine borane is a mild reducing agent. tert-Butylamine borane involves in the selective reduction of aldehydes and ketones to the corresponding alcohols .
    tert-Butylamine borane
  • HY-169218

    BCL6 Cancer
    WK692 is a BCL6 inhibitor that inhibits the BCL6 BTB/SMRT interaction. WK692 can effectively inhibit the growth of diffuse large B-cell lymphoma cells and synergize with EZH2 and PRMT5 inhibitors. .
    WK692
  • HY-177756

    BCL6 Cancer
    BCL6-IN-11 (Compound 8) is an efficient inhibitor that induces partial degradation of BCL6 with its IC50 value for inhibiting the interaction between BCL6 and its co-inhibitory proteins (such as NCOR1) of 6 nM. BCL6-IN-11 can induce approximately 52% degradation of BCL6 after being treated with 5 μM concentration for 90 minutes, and thus is also classified as a partial degrader. BCL6-IN-11 can be used for the study of lymphoma .
    BCL6-IN-11
  • HY-160509

    TRP Channel Neurological Disease
    BTB 06061 is a TRPM7 inhibitor and can be used for study of ischemic disease .
    BTB 06061
  • HY-153691

    mGluR Others
    BTB01303 is a (glutamate release) inhibitor. Cancer cells release high levels of (glutamate), which disrupts normal bone turnover and may lead to cancer-induced bone pain. BTB01303 has the potential to improve cancer-induced bone pain .
    BTB01303
  • HY-P10543

    BCL6 Cancer
    SMRT peptide is one of the co-repressors of BCL6 BTB domain interaction. SMRT peptide binds to the BTB domain of BCL6 and enhances the transcriptional repression function of BCL6. SMRT peptide can be used to study protein-protein interactions .
    SMRT peptide
  • HY-163136

    Autophagy REV-ERB Cancer
    Autophagy/REV-ERB-IN-1 (compound 24) is a dual inhibitor of autophagy and REV-ERB. Autophagy/REV-ERB-IN-1 has anti-tumor activity with a CC50 value of 2.3 μM on BTB-474 cells.
    Autophagy/REV-ERB-IN-1
  • HY-170301

    Quinone Reductase Keap1-Nrf2 Others
    Keap1-IN-1 (Compound 27) is the inhibitor for Keap1, that covalently modifys the Cys151 site in the BTB domain of KEAP1, and interfers with the interaction between Keap-Nrf. Keap1-IN-1 upregulates the mRNA expression of the antioxidant stress element (ARE)-dependent gene NQO1 with an EC50 of 160 nM. Keap1-IN-1 exhibits cytotoxicity in cell U2OS with an EC50 of 527 nM .
    Keap1-IN-1
  • HY-101770R

    Kinesin Microtubule/Tubulin Reference Standards Cancer
    BTB-1 (Standard) is the analytical standard of BTB-1 (HY-101770). This product is intended for research and analytical applications. BTB-1 is a potent, selective and reversible mitotic motor protein Kif18A inhibitor with an IC50 of 1.69 μM.
    BTB-1 (Standard)
  • HY-180166

    BCL6 Cancer
    BCL6-IN-12 (Compound 11e) is a BCL6 inhibitor with a Kd of 0.81 μM. BCL6-IN-12 binds to the BTB domain of BCL6. BCL6-IN-12 can be used in the research of diffuse large B-cell lymphoma .
    BCL6-IN-12
  • HY-108705R

    Molecular Glues Reference Standards Bcl-2 Family Cancer
    BI-3802 (Standard) is the analytical standard of BI-3802 (HY-108705). This product is intended for research and analytical applications. BI-3802, a chemical probe, is a highly potent BCL6 degrader and inhibits the Bric-à-brac (BTB) domain of BCL6 with an IC50 of ≤3 nM. BI-3802 induces the polymerization of BCL6 and promotes BCL6 degration depended on E3 ligase SIAH1. BI-3802 has antitumor activity .
    BI-3802 (Standard)
  • HY-182449

    Bcl-2 Family Cancer
    CCT365386 is a BCL6 inhibitor. CCT365386 serves as an optimized lead compound for cell-active BCL6 degraders (including CCT369260 (HY-129188)). CCT365386 can be used in the research of B-cell lymphoma .
    CCT365386

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: